(AOF) – Abivax announced today that three datasets on its lead drug candidate, obefazimod, will be presented at the United European Week of Gastroenterology (UEG) meeting, October 14-17, 2023, in Copenhagen, Denmark. “We continue to be encouraged by the emerging clinical profile of obefazimod based on the 96-week efficacy and safety data from our Phase 2b open-label maintenance study,” said Sheldon Sloan, Chief Executive Officer. medical of Abivax.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
